Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from BioGaia AB ( ($SE:BIOG.B) ).
BioGaia AB has announced the publication of its new patented strain, L. reuteri BG-R46®, in the journal Beneficial Microbes. Developed in collaboration with the Swedish University of Agricultural Sciences, this strain exhibits enhanced bile tolerance and adenosine production, supporting gut health and anti-inflammatory properties. This advancement underscores BioGaia’s commitment to pioneering microbiome science and maintaining its leadership in the probiotic industry.
The most recent analyst rating on ($SE:BIOG.B) stock is a Buy with a SEK115.00 price target. To see the full list of analyst forecasts on BioGaia AB stock, see the SE:BIOG.B Stock Forecast page.
More about BioGaia AB
BioGaia is a Swedish probiotic company with over 35 years of experience in microbiome research. It develops, manufactures, markets, and sells probiotic products focused on gut, immune, and oral health across more than 100 markets globally. The company’s class B shares are listed on the Mid Cap segment of Nasdaq Stockholm.
Average Trading Volume: 161,006
Technical Sentiment Signal: Buy
Current Market Cap: SEK10.74B
Learn more about BIOG.B stock on TipRanks’ Stock Analysis page.